Joonho Byun1, Seok Ho Hong2, Min Jae Yoon3, Sae Min Kwon1, Young Hyun Cho1, Jeong Hoon Kim1, Chang Jin Kim1. 1. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. 2. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. hongsound@gmail.com. 3. Department of Radiology, Konyang University Hospital, University of Konyang College of Medicine, Daejeon, South Korea.
Abstract
INTRODUCTION: Central neurocytoma (CN) is a very rare neuronal neoplasm. The clinical implications of the potential prognostic factors for these lesions, including tumor atypia, have therefore not been clarified. METHODS: Forty CN patients were enrolled and reclassified as typical or atypical in accordance with an MIB-1 labeling index (LI) of above and below 2%. RESULTS: We classified our retrospective study cohort as 21 (52.5%) typical and 19 (47.5%) atypical CN cases. No significant differences were found in terms of sex, mean age, mean tumor size or tumor location between these groups. Recurrences occurred in 2 (9.5%) typical and 6 (33.3%) atypical cases. The typical CN 2-,3- and 5-year PFS rates were 100%, 100%, 92.3%, and those for the atypical group were 93.8%, 78.1%, 65.1%, respectively (p = 0.02). The PFS rates did not statistically differ by treatment modality (gross total resection alone, subtotal resection (STR) alone and STR plus radiation therapy (RT) or radiosurgery (RS)) either in the whole cohort (p = 0.75) or in the typical CN and atypical CN subgroups (p = 0.45 and 0.98, respectively). An atypical histology was the only prognostic indicator of recurrence by univariate analysis (hazard ratio: 5.40, p = 0.04). CONCLUSIONS: An atypical lesion (MIB-LI > 2%) is an important prognostic indicator in CN. The clinical implications of the extent of resection for CN patients are still debatable. The use of STR plus RT or RS may be a viable treatment strategy for CN but different therapeutic and follow-up approaches for atypical CN will be needed.
INTRODUCTION:Central neurocytoma (CN) is a very rare neuronal neoplasm. The clinical implications of the potential prognostic factors for these lesions, including tumor atypia, have therefore not been clarified. METHODS: Forty CN patients were enrolled and reclassified as typical or atypical in accordance with an MIB-1 labeling index (LI) of above and below 2%. RESULTS: We classified our retrospective study cohort as 21 (52.5%) typical and 19 (47.5%) atypical CN cases. No significant differences were found in terms of sex, mean age, mean tumor size or tumor location between these groups. Recurrences occurred in 2 (9.5%) typical and 6 (33.3%) atypical cases. The typical CN 2-,3- and 5-year PFS rates were 100%, 100%, 92.3%, and those for the atypical group were 93.8%, 78.1%, 65.1%, respectively (p = 0.02). The PFS rates did not statistically differ by treatment modality (gross total resection alone, subtotal resection (STR) alone and STR plus radiation therapy (RT) or radiosurgery (RS)) either in the whole cohort (p = 0.75) or in the typical CN and atypical CN subgroups (p = 0.45 and 0.98, respectively). An atypical histology was the only prognostic indicator of recurrence by univariate analysis (hazard ratio: 5.40, p = 0.04). CONCLUSIONS: An atypical lesion (MIB-LI > 2%) is an important prognostic indicator in CN. The clinical implications of the extent of resection for CN patients are still debatable. The use of STR plus RT or RS may be a viable treatment strategy for CN but different therapeutic and follow-up approaches for atypical CN will be needed.
Entities:
Keywords:
Atypical; Central neurocytoma; Prognosis; Treatment
Authors: James L Leenstra; Fausto J Rodriguez; Christina M Frechette; Caterina Giannini; Scott L Stafford; Bruce E Pollock; Steven E Schild; Bernd W Scheithauer; Robert B Jenkins; Jan C Buckner; Paul D Brown Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-21 Impact factor: 7.038
Authors: Bengt Karlsson; Wan-Yuo Guo; Teo Kejia; Nivedh Dinesh; David Hung-Chi Pan; Hidefumi Jokura; Jun Kawagishi; Albertus T C J van Eck; Gerhard A Horstmann; Tseng Tsai Yeo; Masaaki Yamamoto Journal: J Neurosurg Date: 2012-12 Impact factor: 5.115
Authors: Brandon S Imber; Steve E Braunstein; Fred Y Wu; Nima Nabavizadeh; Nicholas Boehling; Vivian K Weinberg; Tarik Tihan; Michael Barnes; Sabine Mueller; Nicholas A Butowski; Jennifer L Clarke; Susan M Chang; Michael M McDermott; Michael D Prados; Mitchel S Berger; Daphne A Haas-Kogan Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130
Authors: Jennyfer Paulla Galdino Chaves; Carlos Alberto Mattozo; Bruno Augusto Telles; Ana Paula Percicote; Zeferino Jr Demartini; Adriano Keijiro Maeda Journal: Acta Neurol Belg Date: 2020-08-28 Impact factor: 2.396
Authors: Adam Z Kalawi; Denise M Malicki; Zied Abdullaev; Drew W Pratt; Martha Quezado; Kenneth Aldape; Jennifer D Elster; Megan R Paul; Paritosh C Khanna; Michael L Levy; John R Crawford Journal: J Neurooncol Date: 2022-08-22 Impact factor: 4.506
Authors: A Kaywan Aftahy; Melanie Barz; Philipp Krauss; Friederike Liesche; Benedikt Wiestler; Stephanie E Combs; Christoph Straube; Bernhard Meyer; Jens Gempt Journal: BMC Cancer Date: 2020-11-03 Impact factor: 4.430